Published On: Wed, Sep 7th, 2016

Insider Selling: Entellus Medical Inc. (ENTL) Director Sells 11,078 Shares of Stock

Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 11,078 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $18.62, for a total transaction of $206,272.36. Following the transaction, the director now owns 544,581 shares of the company’s stock, valued at $10,140,098.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Several brokerages have commented on ENTL. BTIG Research began coverage on shares of Entellus Medical in a research report on Tuesday, June 14th. They set a “buy” rating and a $22.00 price objective for the company. Bank of America Corp. reiterated a “buy” rating on shares of Entellus Medical in a report on Monday, July 18th. Canaccord Genuity reiterated a “buy” rating and set a $23.00 price target on shares of Entellus Medical in a report on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Monday, August 8th. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $23.00.
Shares of Entellus Medical Inc. (NASDAQ:ENTL) traded down 3.07% during mid-day trading on Tuesday, hitting $18.92. 29,058 shares of the company traded hands. The firm’s 50 day moving average price is $18.37 and its 200-day moving average price is $17.39. Entellus Medical Inc. has a 1-year low of $13.72 and a 1-year high of $23.00. The stock’s market capitalization is $356.62 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.08. The company had revenue of $18.73 million for the quarter, compared to analysts’ expectations of $18.48 million. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.15) EPS. On average, equities research analysts forecast that Entellus Medical Inc. will post ($1.23) EPS for the current year.
Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

Receive News & Ratings for Entellus Medical Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Entellus Medical Inc. and related companies with’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>